Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.20−0.36 (-10.11%)
Close on Nov 16, 2026Market cap $54.97MP/E –Yield –
Verrica Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Verrica Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.62M, up 89.8% year over year. For fiscal 2025 it was $8.86M, down 25.2% from the year before. The highest annual figure on record is $20.30M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.86M | -25.2% |
| FY2024 | Dec 31, 2024 | $11.84M | -41.7% |
| FY2023 | Dec 31, 2023 | $20.30M | +66.4% |
| FY2022 | Dec 31, 2022 | $12.20M | -23.4% |
| FY2021 | Dec 31, 2021 | $15.93M | +1.6% |
| FY2020 | Dec 31, 2020 | $15.67M | +1.5% |
| FY2019 | Dec 31, 2019 | $15.44M | +20.3% |
| FY2018 | Dec 31, 2018 | $12.83M | +243.9% |
| FY2017 | Dec 31, 2017 | $3.73M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.03M | +226.9% |
| Q1 FY2026 | Mar 31, 2026 | $3.86M | +69.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.52M | +115.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.21M | -8.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.85M | -44.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.28M | -53.8% |
| Q4 FY2024 | Dec 31, 2024 | $1.17M | -78.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.41M | -63.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.32M | -42.0% |
| Q1 FY2024 | Mar 31, 2024 | $4.95M | +80.6% |
| Q4 FY2023 | Dec 31, 2023 | $5.32M | +75.7% |
| Q3 FY2023 | Sep 30, 2023 | $6.51M | +134.2% |
| Q2 FY2023 | Jun 30, 2023 | $5.73M | +45.2% |
| Q1 FY2023 | Mar 31, 2023 | $2.74M | +12.0% |
| Q4 FY2022 | Dec 31, 2022 | $3.03M | -9.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.78M | -26.1% |
| Q2 FY2022 | Jun 30, 2022 | $3.94M | +14.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.45M | -54.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.36M | +47.8% |
| Q3 FY2021 | Sep 30, 2021 | $3.76M | -24.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.45M | -2.1% |
| Q1 FY2021 | Mar 31, 2021 | $5.36M | +9.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.27M | -42.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.99M | +63.6% |
| Q2 FY2020 | Jun 30, 2020 | $3.52M | -10.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.89M | +9.0% |
| Q4 FY2019 | Dec 31, 2019 | $3.97M | -19.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.05M | -12.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.93M | +11.7% |
| Q1 FY2019 | Mar 31, 2019 | $4.49M | +384.0% |
| Q4 FY2018 | Dec 31, 2018 | $4.92M | +339.8% |
| Q3 FY2018 | Sep 30, 2018 | $3.47M | +209.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.52M | +259.8% |
| Q1 FY2018 | Mar 31, 2018 | $927.00K | +80.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.12M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.12M | – |
| Q2 FY2017 | Jun 30, 2017 | $977.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $515.00K | – |
See a number that looks wrong?